Genomic, curative drugs for chronic and terminal diseases are perhaps the most exciting new treatments in medicine. But even though these highly tailored therapies come to market with the potential to save costs for the health care system, the industry is struggling to pay for them because of their high up front costs. One expert says that PBMs are well-positioned to sit at the center of new financial models that distribute the high cost and substantial savings equitably across the entire industry.
- Datapoint, Medicare and Medicaid
- Abstract, Health Plans
- People on the Move
- Medicare and Medicaid
- Datapoint, Drug Benefits